IncyteINCY
About: Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Employees: 2,617
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
121% more first-time investments, than exits
New positions opened: 126 | Existing positions closed: 57
86% more call options, than puts
Call options by funds: $68.6M | Put options by funds: $37M
16% more repeat investments, than reductions
Existing positions increased: 238 | Existing positions reduced: 206
14% more funds holding in top 10
Funds holding in top 10: 7 [Q3] → 8 (+1) [Q4]
10% more funds holding
Funds holding: 577 [Q3] → 635 (+58) [Q4]
6% more capital invested
Capital invested by funds: $11.9B [Q3] → $12.6B (+$687M) [Q4]
1.09% more ownership
Funds ownership: 93.56% [Q3] → 94.65% (+1.09%) [Q4]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
Wells Fargo Derek Archila 48% 1-year accuracy 15 / 31 met price target | 6%downside $59 | Equal-Weight Maintained | 30 Apr 2025 |
RBC Capital Brian Abrahams 19% 1-year accuracy 13 / 70 met price target | 7%upside $67 | Sector Perform Maintained | 30 Apr 2025 |
JP Morgan Jessica Fye 55% 1-year accuracy 21 / 38 met price target | 9%upside $68 | Neutral Maintained | 21 Apr 2025 |
Morgan Stanley Vikram Purohit 40% 1-year accuracy 2 / 5 met price target | 4%upside $65 | Equal-Weight Maintained | 24 Mar 2025 |
Truist Securities Srikripa Devarakonda 32% 1-year accuracy 11 / 34 met price target | 15%upside $72 | Hold Maintained | 18 Mar 2025 |
Financial journalist opinion
Based on 12 articles about INCY published over the past 30 days
